{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:59:29Z","timestamp":1791197969811,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02427-8","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:30:19Z","timestamp":1791189019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Known Unknowns: Unpacking Controversies and Uncertainties in the 2025 Guidelines for Management of Acute Coronary Syndromes"],"prefix":"10.1007","volume":"28","author":[{"given":"Valentina Jaramillo","family":"Restrepo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2427_CR1","unstructured":"Rao SV, et al. ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation. 2025;151(13):e771\u2013862."},{"issue":"4","key":"2427_CR2","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127(4):e362\u2013425.","journal-title":"Circulation"},{"issue":"25","key":"2427_CR3","first-page":"e344","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, et al. 2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes. Circulation. 2014;130(25):e344\u2013426.","journal-title":"Circulation"},{"issue":"11","key":"2427_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/CIR.0000000000000336","volume":"133","author":"GN Levine","year":"2016","unstructured":"Levine GN, et al. ACC\/AHA\/SCAI focused update on primary percutaneous coronary intervention for patients With ST-elevation myocardial infarction: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF\/AHA guideline for t. Circulation. 2016;133(11):1135\u201347.","journal-title":"Circulation"},{"issue":"2","key":"2427_CR5","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","volume":"79","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, et al. ACC\/AHA\/SCAI guideline for coronary artery revascularization. J Am Coll Cardiol. 2022;79(2):e21\u2013129.","journal-title":"J Am Coll Cardiol"},{"issue":"9957","key":"2427_CR6","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","volume":"384","author":"A Shahzad","year":"2014","unstructured":"Shahzad A, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014;384(9957):1849\u201358.","journal-title":"Lancet"},{"issue":"21","key":"2427_CR7","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"GW Stone","year":"2008","unstructured":"Stone GW, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218\u201330.","journal-title":"N Engl J Med"},{"issue":"11","key":"2427_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1507854","volume":"373","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015;373(11):997\u20131009.","journal-title":"N Engl J Med"},{"issue":"4","key":"2427_CR9","first-page":"226","volume":"2","author":"Z Liang","year":"2022","unstructured":"Liang Z, et al. Rationale and design of a randomized controlled trial of bivalirudin with a prolonged high-dose infusion versus heparin monotherapy during primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: the BR. Cardiol Discov. 2022;2(4):226\u201330.","journal-title":"Cardiol Discov"},{"issue":"10366","key":"2427_CR10","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","volume":"400","author":"Y Li","year":"2022","unstructured":"Li Y, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022;400(10366):1847\u201357.","journal-title":"Lancet"},{"issue":"16","key":"2427_CR11","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jacc.2024.07.045","volume":"84","author":"GW Stone","year":"2024","unstructured":"Stone GW, et al. Bivalirudin vs heparin anticoagulation in STEMI. J Am Coll Cardiol. 2024;84(16):1512\u201324.","journal-title":"J Am Coll Cardiol"},{"key":"2427_CR12","unstructured":"Ahmad Y, et al. Complete revascularization by percutaneous coronary intervention for patients with ST\u2010segment\u2013elevation myocardial infarction and multivessel coronary artery disease: an updated meta\u2010analysis of randomized trials. J Amer Heart Assoc. 2020;9(12):e015263."},{"issue":"15","key":"2427_CR13","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1056\/NEJMoa1907775","volume":"381","author":"SR Mehta","year":"2019","unstructured":"Mehta SR, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381(15):1411\u201321.","journal-title":"N Engl J Med"},{"issue":"15","key":"2427_CR14","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1056\/NEJMoa2307823","volume":"389","author":"BE St\u00e4hli","year":"2023","unstructured":"St\u00e4hli BE, et al. Timing of complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2023;389(15):1368\u201379.","journal-title":"N Engl J Med"},{"issue":"10383","key":"2427_CR15","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S0140-6736(23)00351-3","volume":"401","author":"R Diletti","year":"2023","unstructured":"Diletti R, et al. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet. 2023;401(10383):1172\u201382.","journal-title":"Lancet"},{"issue":"10","key":"2427_CR16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2300468","volume":"389","author":"S Biscaglia","year":"2023","unstructured":"Biscaglia S, et al. Complete or culprit-only PCI in older patients with myocardial infarction. N Engl J Med. 2023;389(10):889\u201398.","journal-title":"N Engl J Med"},{"issue":"18","key":"2427_CR17","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1001\/jama.2021.18323","volume":"326","author":"MD Samsky","year":"2021","unstructured":"Samsky MD, et al. Cardiogenic shock after acute myocardial infarction. JAMA. 2021;326(18):1840.","journal-title":"JAMA"},{"issue":"14","key":"2427_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","volume":"367","author":"H Thiele","year":"2012","unstructured":"Thiele H, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287\u201396.","journal-title":"N Engl J Med"},{"issue":"14","key":"2427_CR19","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJMoa2307227","volume":"389","author":"H Thiele","year":"2023","unstructured":"Thiele H, et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med. 2023;389(14):1286\u201397.","journal-title":"N Engl J Med"},{"issue":"8","key":"2427_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1001\/jama.2020.0254","volume":"323","author":"SS Dhruva","year":"2020","unstructured":"Dhruva SS, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2020;323(8):734.","journal-title":"JAMA"},{"issue":"21","key":"2427_CR21","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2022.08.807","volume":"80","author":"M Pahuja","year":"2022","unstructured":"Pahuja M, et al. Randomized trials of percutaneous microaxial flow pump devices. J Am Coll Cardiol. 2022;80(21):2028\u201349.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2427_CR22","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","volume":"390","author":"JE M\u00f8ller","year":"2024","unstructured":"M\u00f8ller JE, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med. 2024;390(15):1382\u201393.","journal-title":"N Engl J Med"},{"key":"2427_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-025-02243-6","author":"S Waxman","year":"2025","unstructured":"Waxman S, Bajwa U, Tran M. Intravascular coronary imaging update: advances, clinical applications, and future directions. Curr Cardiol Rep. 2025. https:\/\/doi.org\/10.1007\/s11886-025-02243-6.","journal-title":"Curr Cardiol Rep"},{"issue":"18","key":"2427_CR24","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1056\/NEJMoa2216607","volume":"388","author":"JM Lee","year":"2023","unstructured":"Lee JM, et al. Intravascular Imaging-Guided or Angiography-Guided Complex PCI. N Engl J Med. 2023;388(18):1668\u201379.","journal-title":"N Engl J Med"},{"issue":"16","key":"2427_CR25","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa2307770","volume":"389","author":"NR Holm","year":"2023","unstructured":"Holm NR, et al. OCT or angiography guidance for PCI in complex bifurcation lesions. N Engl J Med. 2023;389(16):1477\u201387.","journal-title":"N Engl J Med"},{"issue":"16","key":"2427_CR26","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1161\/CIRCULATIONAHA.123.066429","volume":"148","author":"D-Y Kang","year":"2023","unstructured":"Kang D-Y, et al. Optical coherence tomography\u2013guided or intravascular ultrasound\u2013guided percutaneous coronary intervention: the OCTIVUS randomized clinical trial. Circulation. 2023;148(16):1195\u2013206.","journal-title":"Circulation"},{"issue":"10429","key":"2427_CR27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(23)02454-6","volume":"403","author":"GW Stone","year":"2024","unstructured":"Stone GW, et al. Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis. Lancet. 2024;403(10429):824\u201337.","journal-title":"Lancet"},{"issue":"22","key":"2427_CR28","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/j.jacc.2025.01.018","volume":"85","author":"DJ Kumbhani","year":"2025","unstructured":"Kumbhani DJ, Cibotti-Sun M, Moore MM. 2025 Acute coronary syndromes guideline-at-a-glance. J Am Coll Cardiol. 2025;85(22):2128\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"2427_CR29","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"18","key":"2427_CR30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"2427_CR31","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"10456","key":"2427_CR32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","volume":"404","author":"M Valgimigli","year":"2024","unstructured":"Valgimigli M, et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024;404(10456):937\u201348.","journal-title":"Lancet"},{"issue":"6","key":"2427_CR33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jcin.2022.01.002","volume":"15","author":"A Elbadawi","year":"2022","unstructured":"Elbadawi A, et al. FFR- versus angiography-guided revascularization for nonculprit stenosis in STEMI and multivessel disease. JACC Cardiovasc Interv. 2022;15(6):656\u201366.","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"2427_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMoa2104650","volume":"385","author":"E Puymirat","year":"2021","unstructured":"Puymirat E, et al. Multivessel PCI guided by FFR or angiography for myocardial infarction. N Engl J Med. 2021;385(4):297\u2013308.","journal-title":"N Engl J Med"},{"issue":"1","key":"2427_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52427","volume":"7","author":"D Hong","year":"2024","unstructured":"Hong D, et al. Cost-effectiveness of fractional flow reserve-guided treatment for acute myocardial infarction and multivessel disease. JAMA Netw Open. 2024;7(1):e2352427.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2427_CR36","first-page":"1523","volume":"105","author":"FTW Groenland","year":"2025","unstructured":"Groenland FTW, et al. Impact of post percutaneous coronary intervention fractional flow reserve on 5-year clinical outcomes (The FFR SEARCH Study). Catheter Cardiovasc Interv. 2025;105(6):1523\u20139.","journal-title":"Catheter Cardiovasc Interv"},{"key":"2427_CR37","unstructured":"Shamir Mehta TM. COMPLETE-2Physiology-guided versus angiography-guided complete revascularization to treat multivessel disease after early PCI for STEMI and NSTEMI. Available from: https:\/\/www.phri.ca\/research\/complete-2\/."},{"key":"2427_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ahj.2018.03.024","volume":"202","author":"WW O'Neill","year":"2018","unstructured":"O\u2019Neill WW, et al. Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device. Am Heart J. 2018;202:33\u20138.","journal-title":"Am Heart J"},{"key":"2427_CR39","doi-asserted-by":"crossref","unstructured":"Testa L, et al. IVUS-guided versus angiography-guided PCI in unprotected left main coronary disease. New Engl J Med. 2026;394:2189\u201399.","DOI":"10.1056\/NEJMoa2600440"},{"key":"2427_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ahj.2020.08.002","volume":"228","author":"E Shlofmitz","year":"2020","unstructured":"Shlofmitz E, et al. The IMPact on Revascularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and Economic impact (IMPROVE) trial: study design and rationale. Am Heart J. 2020;228:65\u201371.","journal-title":"Am Heart J"},{"issue":"14","key":"2427_CR41","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMoa2600283","volume":"394","author":"Y-J Lee","year":"2026","unstructured":"Lee Y-J, et al. Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease. N Engl J Med. 2026;394(14):1365\u201375.","journal-title":"N Engl J Med"},{"issue":"3","key":"2427_CR42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/0735-1097(93)90213-K","volume":"22","author":"RS Rosenson","year":"1993","unstructured":"Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22(3):933\u201340.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2427_CR43","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jacc.2007.11.075","volume":"51","author":"B Pitt","year":"2008","unstructured":"Pitt B, et al. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. 2008;51(15):1440\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"2427_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2022.01.058","volume":"171","author":"MA Vavuranakis","year":"2022","unstructured":"Vavuranakis MA, et al. The trajectory of lipoprotein(a) during the peri- and early postinfarction period and the impact of proprotein convertase subtilisin\/kexin type 9 inhibition. Am J Cardiol. 2022;171:1\u20136.","journal-title":"Am J Cardiol"},{"issue":"9","key":"2427_CR45","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060.","journal-title":"JAMA Cardiol"},{"key":"2427_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2026.107430","author":"C Iribarren","year":"2026","unstructured":"Iribarren C, et al. Attaining LDL-cholesterol target post major coronary event: care gap, associated factors and clinical outcomes. Am Heart J. 2026. https:\/\/doi.org\/10.1016\/j.ahj.2026.107430.","journal-title":"Am Heart J"},{"issue":"9","key":"2427_CR47","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.3390\/jcm14092992","volume":"14","author":"D D\u2019Andrea","year":"2025","unstructured":"D\u2019Andrea D, et al. PCSK9 inhibitors \u201cfast track\u201d use versus \u201cstepwise\u201d lipid-lowering therapy in patients with acute coronary syndrome: a retrospective single-center study in a \u201creal-world\u201d population. J Clin Med. 2025;14(9):2992.","journal-title":"J Clin Med"},{"issue":"15","key":"2427_CR48","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","volume":"31","author":"P Gargiulo","year":"2024","unstructured":"Gargiulo P, et al. Strike early\u2013strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry. Eur J Prev Cardiol. 2024;31(15):1806\u201316.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"2427_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","volume":"147","author":"J Kang","year":"2023","unstructured":"Kang J, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation. 2023;147(2):108\u201317.","journal-title":"Circulation"},{"issue":"10486","key":"2427_CR50","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","volume":"405","author":"KH Choi","year":"2025","unstructured":"Choi KH, et al. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial. Lancet. 2025;405(10486):1252\u201363.","journal-title":"Lancet"},{"key":"2427_CR51","doi-asserted-by":"crossref","unstructured":"Watanabe H, et al. Clopidogrel versus aspirin monotherapy beyond 1 year after PCI: the final 5-year results of the STOPDAPT-2 ACS and STOPDAPT-2 total cohort. Circ Cardiovasc Interv. 2026;9:e016280.","DOI":"10.1161\/CIRCINTERVENTIONS.125.016280"},{"issue":"21","key":"2427_CR52","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032\u201342.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02427-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02427-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02427-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:02:37Z","timestamp":1791194557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02427-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2427"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02427-8","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"25 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relationships with industry to declare.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Central Fig.\u00a0\n                      \n                      is an AI-generated image. Other AI tools were applied for grammar correction and sentence restructuring.","order":3,"name":"Ethics","label":"Use of Artificial Intelligence","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"105"}}